Future studies should also examine the expression of LEDGF/p75 in relationship to tumor stage and grade, tumor microenvironment, tumor mutational status, and therapeutic modalities, in large cohorts of racially/ethnically diverse cancer patients with annotated genomics, transcriptomics, and clinicopathological data. This evidence concerns the gene PSIP1 and neoplasm.